{"drugs":["Thioplex","Thiotepa"],"mono":{"0":{"id":"626085-s-0","title":"Generic Names","mono":"Thiotepa"},"1":{"id":"626085-s-1","title":"Dosing and Indications","sub":[{"id":"626085-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Breast adenocarcinoma:<\/b> 0.3 to 0.4 mg\/kg IV at 1 to 4 wk intervals; initially, higher dose is commonly given; maintenance dose based on blood counts<\/li><li><b>Carcinoma of bladder, Superficial papillary:<\/b> dehydrate patient for 8 to 12 hours prior to therapy, then give 60 mg in 30 to 60 mL NS for INTRAVESICAL administration once weekly for 4 weeks; patient should retain solution for 2 hours; may repeat monthly if necessary (with caution)<\/li><li><b>Carcinoma of bladder; Prophylaxis:<\/b> Optimal dose and timing of thiotepa has not been defined in this setting; clinical trials have used doses of 30 mg INTRAVESICALLY by bladder instillation weekly for 4 weeks, then every 4 weeks for 11 months; doses of 50 mg have also been used.<\/li><li><b>Hodgkin's disease:<\/b> 0.3 to 0.4 mg\/kg IV at 1 to 4 wk intervals; initially, higher dose is commonly given; maintenance dose based on blood counts<\/li><li><b>Malignant effusion, Intracavitary:<\/b> 0.6 to 0.8 mg\/kg INTRACAVITARY<\/li><li><b>Malignant meningitis:<\/b> Optimal dose and timing of thiotepa has not been defined in this setting; one clinical trial used INTRAVENTRICULAR thiotepa 10 mg in 10 mL of buffered diluent, on day 1 and methotrexate 10 mg in 10 mL of buffered diluent, on day 4 on a weekly basis for 8 or 12 weeks in conjunction with radiation therapy<\/li><li><b>Ovarian cancer, Adenocarcinoma:<\/b> 0.3 to 0.4 mg\/kg IV at 1 to 4 wk intervals; initially, higher dose is commonly given; maintenance dose based on blood counts<\/li><\/ul>"},{"id":"626085-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in children have not been established"},{"id":"626085-s-1-6","title":"Dose Adjustments","mono":"<b>hematologic:<\/b> WBC count less than 3,000\/mm(3) or platelet count less than 150,000\/mm(3)),  discontinue therapy"},{"id":"626085-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Breast adenocarcinoma<\/li><li>Carcinoma of bladder, Superficial papillary<\/li><li>Hodgkin's disease<\/li><li>Malignant effusion, Intracavitary<\/li><li>Ovarian cancer, Adenocarcinoma<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bone marrow transplant<\/li><li>Carcinoma of bladder; Prophylaxis<\/li><li>Leukemia<\/li><li>Malignant meningitis<\/li><li>Non-Hodgkin's lymphoma<\/li><li>Pterygium<\/li><\/ul>"}]},"3":{"id":"626085-s-3","title":"Contraindications\/Warnings","sub":[{"id":"626085-s-3-9","title":"Contraindications","mono":"<ul><li>existing hepatic, renal or bone marrow damage (may use low dosage and frequent monitoring if need outweighs risk)<\/li><li>hypersensitivity to thiotepa<\/li><\/ul>"},{"id":"626085-s-3-10","title":"Precautions","mono":"<ul><li>intravesical administration may be fatal<\/li><li>highly toxic to hematopoietic system<\/li><li>avoid other drugs that produce bone marrow suppression<\/li><li>carcinogenic<\/li><li>do not administer with other alkylating chemotherapeutic agents, intensified toxicity<\/li><li>use effective contraception during therapy<\/li><li>use proper procedures for handling and disposal of chemotherapy<\/li><\/ul>"},{"id":"626085-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"626085-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"626085-s-4","title":"Drug Interactions","sub":[{"id":"626085-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"626085-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Bupropion (theoretical)<\/li><li>Fosphenytoin (probable)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Phenytoin (probable)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"},{"id":"626085-s-4-15","title":"Moderate","mono":"<ul><li>Cyclophosphamide (probable)<\/li><li>Efavirenz (probable)<\/li><li>Ifosfamide (probable)<\/li><li>Methadone (probable)<\/li><li>Sertraline (probable)<\/li><li>Sorafenib (probable)<\/li><\/ul>"}]},"5":{"id":"626085-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia, Injection site pain, Rash<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Asthenia<\/li><li><b>Other:<\/b>Fatigue<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Acute myeloid leukemia, Myelosuppression<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, Myelodysplastic syndrome<\/li><li><b>Reproductive:<\/b>Amenorrhea, Oligozoospermia<\/li><\/ul>"},"6":{"id":"626085-s-6","title":"Drug Name Info","sub":{"0":{"id":"626085-s-6-17","title":"US Trade Names","mono":"Thioplex<br\/>"},"2":{"id":"626085-s-6-19","title":"Class","mono":"<ul><li>Alkylating Agent<\/li><li>Antineoplastic Agent<\/li><li>Nitrogen Mustard<\/li><\/ul>"},"3":{"id":"626085-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"626085-s-7","title":"Mechanism Of Action","mono":"Thiotepa is a cytotoxic, ethylenimine-type agent related to nitrogen mustard, which acts by releasing ethylenimine radicals that disrupts DNA bonds and causes the breakage of links between the purine base and sugar, liberating alkylated guanines, resulting in the misreading of the DNA code and the inhibition of DNA, RNA, and protein synthesis in rapidly proliferating tumor cells.<br\/>"},"8":{"id":"626085-s-8","title":"Pharmacokinetics","sub":[{"id":"626085-s-8-23","title":"Absorption","mono":"Bioavailability, Oral: incomplete <br\/>"},{"id":"626085-s-8-24","title":"Distribution","mono":"Vd: 0.3 to 1.6 L\/kg <br\/>"},{"id":"626085-s-8-25","title":"Metabolism","mono":"<ul><li>Liver<\/li><li>Metabolite, tepa: active<\/li><li>Potent inhibitor of CYP2B6<\/li><\/ul>"},{"id":"626085-s-8-26","title":"Excretion","mono":"<ul><li>Renal: less than 2% unchanged; 4.2% as active metabolite<\/li><li>Total body clearance: 419 to 446 mL\/min<\/li><li>Dialyzable: Yes<\/li><\/ul>"}]},"9":{"id":"626085-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>for IV, intracavitary, or intravesical administration only; do not administer orally<\/li><li>follow procedures for the proper handling and disposal of cytotoxic drugs; use gloves<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute with 1.5 mL Sterile Water for Injection to give a final concentration of approximately 10 mg\/mL; dilute with NS immediately before use<\/li><li>filter solutions through 0.22 micron filter prior to administration<\/li><li>administer by rapid IV injection<\/li><\/ul><\/li><\/ul>"},"10":{"id":"626085-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response<\/li><li>CBC; weekly during therapy and for at least 3 weeks after cessation of therapy<\/li><\/ul>"},"12":{"id":"626085-s-12","title":"Toxicology","sub":[{"id":"626085-s-12-31","title":"Clinical Effects","mono":"<b>THIOTEPA<\/b><br\/>OVERDOSE: Limited data available. Overdose effects are likely to be an extension of adverse effects reported. Hematopoietic toxicity is anticipated. Bleeding may develop. ADVERSE EVENTS: Bone marrow depression, primarily leukopenia, thrombocytopenia and anemia are the most common effects of thiotepa therapy. Nausea, vomiting, abdominal pain, anorexia, dizziness, headache, blurred vision as well as allergic reactions including anaphylactic shock have occurred with therapeutic use. Cases of chemical cystitis or hemorrhagic cystitis have been reported following thiotepa intravesical administration. RARE: Alopecia.<br\/>"},{"id":"626085-s-12-32","title":"Treatment","mono":"<b>THIOTEPA<\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Myelosuppression: Monitor CBC with differential and platelet count. For severe neutropenia, administer filgrastim 5 mcg\/kg\/day subcutaneously, or sargramostim 250 mcg\/m(2)\/day infused over 4 hours. Platelet transfusions for severe thrombocytopenia. Packed red cells may be necessary.<\/li><li>Hemodialysis: Thiotepa is dialyzable.<\/li><li>Intrathecal injection: No clinical reports available, information derived from experience with other antineoplastics. Keep patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults.  Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free 0.9% saline).  Consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr for 18 to 24 hr).  FFP (25 ml FFP\/liter NS) or albumin 5% have also been used for perfusion. Dexamethasone 4 mg IV every 6 hours to prevent arachnoiditis<\/li><li>Monitoring of patient: Monitor vital signs including temperature and blood pressure. Monitor CBC with differential, platelet count, and fluid and electrolyte status.<\/li><\/ul>"},{"id":"626085-s-12-33","title":"Range of Toxicity","mono":"<b>THIOTEPA<\/b><br\/>TOXICITY: Doses at or slightly above the therapeutic dose have resulted in life threatening myelosuppression. THERAPEUTIC: 0.3 to 0.4 mg\/kg IV at 1 to 4 week intervals, or 0.6 to 0.8 mg\/kg intracavitary or 60 mg in 30 to 60 mL NS for intravesical administration once weekly. <br\/>"}]},"13":{"id":"626085-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Counsel patient that drug may cause infertility in both men and women. Family planning should be discussed with a healthcare professional before initiating drug therapy.<\/li><li>Adverse effects to a fetus may be caused by either male or female patients receiving treatment with this drug. Emphasize the use of reliable contraception to patient.<\/li><li>This drug may cause alopecia, injection site pain, anorexia, nausea, vomiting, asthenia, fatigue, or amenorrhea.<\/li><li>Tell patient to report signs\/symptoms of myelosuppression.<\/li><\/ul>"}}}